Latest news with #SudarshanPharmaIndustries
India.com
05-05-2025
- Business
- India.com
325% return in 5 years: This multibagger stock in focus after H2 FY2025 results
Stock market news: There are stocks that have given multibagger returns to their investors. One such stock is of small-cap pharma company, Sudarshan Pharma Industries Ltd. The company's share price is in focus today during the trading session. The reason for this is that the company has announced its March quarter and FY 2025 results on Friday. Multibagger Pharma Stock closed at Rs 26.66 on May 2 with a decline of 1.99 per cent. The stock opened flat today but surged to hit the intraday high of Rs 27.99 on the BSE. Sudarshan Pharma Industries shares have given more than 325 per cent return in 5 years. In the second half of FY 2025, i.e. October 2024 to March 2025 (H2FY25), net sales of Sudarshan Pharma Industries Limited increased by 19 per cent to Rs 277 crore as compared to the same period a year ago. Net profit increased by 43 per cent to Rs 7 crore. EBITDA (Earnings before Interest, Taxes, Depreciation and Amortization) margin also saw a good increase in H2FY25. For the full financial year 2024-25, the company's net sales grew by 9 per cent to Rs 505 crore, while net profit grew by 45 per cent to Rs 16 crore. The company's market cap is Rs 642 crore. The company's compound annual profit growth has been 37 per cent in the last 5 years. India's pharmaceutical industry was worth around $42 billion in the year 2021. It can reach around $66 billion by 2025, while it can grow to $120-130 billion by 2030. During the March 2025 quarter, the company's revenue from operations grew 16.6 per cent year-on-year to Rs 277.26 crore from Rs 237.74 crore in the March 2024 quarter. Sudarshan Pharma Industries has reported a net profit of Rs 10.03 crore during the quarter ended March 31, 2025. This profit is about 52 per cent higher than the net profit of Rs 6.64 crore recorded during the quarter ended March 31, 2024. The pharma company told its investors that SPIL is working on boosting its exports. Along with this, it is actively working to increase domestic sales of its manufactured medicines. Apart from this, the company aims to improve profit margins by reselling active pharmaceutical ingredients (APIs) in India. Let us tell you that Sudarshan Pharma Industries manufactures specialty chemicals and intermediates for pharma, agro chemicals, paints, adhesives and other industries.
Mint
04-05-2025
- Business
- Mint
325% rally in five years! Multibagger pharma stock in focus; here's why
Multibagger stock: Pharma company Sudarshan Pharma Industries share price will remain in focus in Monday's trading session after the company reported its half yearly and FY25 financial & operational performance on Friday. The multibagger pharma stock was down 1.99 per cent to close at ₹ 26.66 apiece on May 2. Sudarshan Pharma Industries shares have given mutlibagger returns to its investors by soaring over 325 per cent in five years. In the second half of FY25 (H2FY25), Sudarshan Pharma Industries Limited (SPIL) reported a 19% rise in net sales to ₹ 277 crore and a 43% increase in net profit to ₹ 7 crore compared to H2FY24. For the full fiscal year FY25, net sales rose by 9% to ₹ 505 crore, while net profit surged by 45% to ₹ 16 crore year-on-year. The company, currently valued at ₹ 642 crore in market capitalization, has achieved a strong compound annual profit growth of 37% over the past five years. SPIL is actively working to boost its exports and increase domestic sales of its manufactured medicines, the pharma company said in its investor's presentation. Additionally, it aims to improve profit margins from reselling Active Pharmaceutical Ingredients (API) in India. This strategic focus contributed to a significant rise in EBITDA margin in H2FY25, which in turn drove strong growth in Profit After Tax during the same period. India's pharmaceutical industry was valued at approximately $42 billion in 2021 and is projected to rise to around $50 billion by 2024. Forecasts suggest it could reach nearly $66 billion by 2025 and potentially expand to between $120 billion and $130 billion by 2030. India fulfills 40% of the United States' generic drug requirements and supplies 25% of the medicines used in the United Kingdom. Globally, India contributes 20% of total medicine production by volume and meets about 60% of the world's vaccine demand, solidifying its position as the leading supplier of generic drugs. Founded in 2008, Sudarshan Pharma is engaged in manufacturing and sourcing of Chemicals and Pharmaceutical products. The Company specializes in host of products from rock chemicals intermediates and API to finish formulations and fully integrated pharmaceutical and chemicals. Disclaimer: This story is for educational purposes only. The views and recommendations above are those of individual analysts or broking companies, not Mint. We advise investors to check with certified experts before making any investment decisions. First Published: 4 May 2025, 01:51 PM IST
Mint
25-04-2025
- Business
- Mint
250% rally in one year! Multibagger pharma stock jumps despite stock market crash
Stock Market Today: With 250% rally in one year the Multibagger pharma stock gained further on the BSE on Friday, during the intraday trades despite stock market crash. The Sudarshan Pharma Industries Ltd reported its financial performance for the quarter ending March'2025 and the finanial year Sudarshan Pharma Industries reported net profit at ₹ 10.03 crore during the quarter ending 31 March 2025 skyrocketed around 52% compared to ₹ 6.64 crore net profit clocked by Sudarshan Pharma Industries during the quarter ending 31 March 2024. At the Standalone during the January to March 2025 quarter, the Sudarshan Pharma Industries net profit at ₹ 9.95 crore also saw a sharp rise The net profit for the quarter reported buy the Sudarshan Pharma Industries grew sharp 54% compared to ₹ 6.46 crore reported in the year ago quarter The consolidated revenues of operations for Sudarshan Pharma Industries that came at ₹ 277.26 crore during the quarter ending March 2024 saw a strong 16.6% rise over ₹ 237. 74 crore The revenues from operations for Sudarshan Pharma Industries for the quarter ending March 2025 came at ₹ 277..6 crore saw a sharp jump of 18.8% companied to ₹ 233.76 crore reported in the January _ March 2024 quarter. Sudarshan Pharma Industries share price opened almost flat at ₹ share price opened at ₹ 27.80 levels on the BSE on Friday. At the time of opening, the Sudarshan Pharma Industries share price was almost 2% higher compared to the previous day's closing price of ₹ 27.26 .Sudarshan Pharma Industries share price however continued to trade at similar levels during the intra day trades on Friday despite weakness in Indian stock Markets on a day when the Sensex was trading 1.4-15% lower as stock market crashed. Notably the Sudarshan Pharma Industries share price had hit the upper price band and hence the Sudarshan Pharma Industries share price was locked in the upper circuit on Friday. Disclaimer: The views and recommendations given in this article are those of individual analysts. These do not represent the views of Mint. We advise investors to check with certified experts before making any investment decisions. First Published: 25 Apr 2025, 12:11 PM IST
